Loading
Larkspur Biosciences makes medicines that remove proteins tumours rely on to survive stress. Its first medicine, taken daily, is being tested in solid tumours with a focus on bowel cancer, alone and with chemotherapy.
Larkspur Biosciences Inc., at One Canal Park, Cambridge, Massachusetts, develops first-in-class protein degraders aimed at stress-response pathways that tumours depend on, according to its website. Its lead LRK-4189, taken daily, is in a phase 1b/2 dose-escalation, expansion and optimisation trial (NCT07498725) alone and with mFOLFOX6 or FOLFIRI in solid tumours with a focus on colorectal cancer, at sites in Edinburgh, Nice and Strasbourg. Its first registered cancer trial, NCT07498725, was posted on ClinicalTrials.gov in March 2026.
Shares PROTACs & molecular glues (targeted protein degradation), Colorectal cancer.
Shares PROTACs & molecular glues (targeted protein degradation), Colorectal cancer.
Shares PROTACs & molecular glues (targeted protein degradation), Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/